

537,968

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052298 A2

(51) International Patent Classification⁷:

A61K

(74) Agent: ROSENFELD, Susan, Stone; Fennemore Craig,
3003 North Central, Suite 2600, Phoenix, AZ 85012-2913
(US).

(21) International Application Number:

PCT/US2003/039067

(81) Designated States (*national*): CA, JP, US.

(22) International Filing Date: 9 December 2003 (09.12.2003)

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/432,219 9 December 2002 (09.12.2002) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations CA, JP, European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
- of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (*for all designated States except US*): ARI-
ZONA BOARD OF REGENTS, a body corporate of the
State of Arizona, acting for and on behalf of ARIZONA
STATE UNIVERSITY [US/US]; Box 879209, Tempe,
AZ 85287 (US).

Published:


- without international search report and to be republished upon receipt of that report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): PETTIT, George,
R. [US/US]; 6232 Bret Hills Drive, Paradise Valley, AZ
85253 (US). MELODY, Noleen [IE/US]; 7032 East In-
digo Street, Mesa, AZ 85207 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NARCISTATIN PRODRUGS



(57) Abstract: The present invention provides prodrugs derived from the sparingly soluble anticancer isocarbostryl narciclasine, a component of various *Narcissus* species, said prodrugs having potential for use against animal and human cancers. Also disclosed is an efficient procedure for the synthetic conversion of narciclasine to several more soluble cyclic phosphate compounds, including "narcistatin".

WO 2004/052298 A2